https://www.metriopharm.com/en/ https://www.metriopharm.com/de/ https://www.metriopharm.com/de/Ueber-uns/MetrioPharm-AG-ueber-uns.html https://www.metriopharm.com/de/Investoren/IR-News.html https://www.metriopharm.com/de/Presse/Pressemitteilungen.html https://www.metriopharm.com/en/about-us/Our-Company.html https://www.metriopharm.com/en/pipeline/indications.html https://www.metriopharm.com/en/investors/investor-relations-news.html https://www.metriopharm.com/en/press/press-releases.html https://www.metriopharm.com/de/News/2016/Rekrutierung-Studie-MP1032-Psoriasis-abgeschlossen.html https://www.metriopharm.com/de/News/2015/Leitsubstanz-MP1032-Phase-I-erfolgreich-abgeschlossen.html https://www.metriopharm.com/de/News/2014/Neues-Mitglied-des-Verwaltungsrats.html https://www.metriopharm.com/en/news/2015/Phase-I-successfully-completed.html https://www.metriopharm.com/en/news/2014/Rt-Hon-David-Davis-New-Member-of-the-Board.html https://www.metriopharm.com/de/Investor-News/2015/Jahresrueckblick-des-Praesidenten-des-Verwaltungsrats.html https://www.metriopharm.com/de/Investor-News/2014/Juli-2014-Generalversammlung.html https://www.metriopharm.com/en/investor-news/2015/Annual-Review-from-the-President-of-the-Board-2015.html https://www.metriopharm.com/en/investor-news/2014/Annual-General-Meeting-2014.html https://www.metriopharm.com/en/news/2016/Recruiting-MP1032´-trial-psoriasis-completed.html https://www.metriopharm.com/en/investor-news/2016/MetrioPharm-Investor-Relations-News-December-2016.html https://www.metriopharm.com/de/News/2017/MP1032-Patentschutz-Suedkorea.html https://www.metriopharm.com/en/investor-news/2017/MetrioPharm-Investor-Relations-News-QIII-2017.html https://www.metriopharm.com/de/Investor-News/2017/MetrioPharm-Investor-Relations-News-QIV-2017.html https://www.metriopharm.com/en/investor-news/2017/MetrioParm-Investor-Relations-News-QIII-2017.html https://www.metriopharm.com/de/News/2018/pressemitteilung-vom-111218.html https://www.metriopharm.com/en/news/2018/pressrelease-december112018.html https://www.metriopharm.com/de/Pipeline/indikationen.html https://www.metriopharm.com/de/News/2022/Top-Line-Daten-der-Phase-IIa-Studie-bei-COVID-19-Patienten-mit-MP1032.html https://www.metriopharm.com/de/News/2023/Oktober-MetrioPharm-erhaelt-von-der-US-Zulassungsbehoerde-FDA-den-Status-einer-Seltenen-Paediatrischen-Krankheit-fuer-MP1032.html https://www.metriopharm.com/de/News/2017/MetrioPharmAG-positive-Top-Line-Ergebnisse.html https://www.metriopharm.com/de/Presse/Unternehmenskalender.html https://www.metriopharm.com/de/Investoren/geschaeftsbericht-und-statuten.html https://www.metriopharm.com/de/Kontakt/kontakt.html https://www.metriopharm.com/en/technology/MP1000-Platform.html https://www.metriopharm.com/de/News/2022/praeklinische-Experimente-in-Duchenne-Muskeldystrophie-(DMD).html https://www.metriopharm.com/en/press/company-calendar.html https://www.metriopharm.com/en/investors/financial-report-and-statutes.html https://www.metriopharm.com/en/Contact/contact.html https://www.metriopharm.com/de/News/2016/Patentschutz-fuer-Leitsubstanz-MP1032-erweitert.html https://www.metriopharm.com/de/News/2015/Behoerden-genehmigen-zweiten-Teil-Phase-I-Studie.html https://www.metriopharm.com/de/News/2014/Antrag-fuer-klinische-Phase-I-Studie-fuer-MP1032-beim-BfArM-eingereicht.html https://www.metriopharm.com/en/news/2014/phase-I-investigational-new-drug-application-for-lead-compound-MP1032-submitted.html https://www.metriopharm.com/en/news/2016/Patent-Protection-for-Lead-Compound-MP1032.html https://www.metriopharm.com/en/news/2015/second-part-of-phase-I-safety-study-cleared-by-authorities.html https://www.metriopharm.com/de/Investor-News/2015/Zweiter-Teil-der-Phase-I-Studie-von-Behoerden-genehmigt.html https://www.metriopharm.com/de/Investor-News/2014/Patente.html https://www.metriopharm.com/en/investor-news/2015/Phase-I-Safety-Study-cleared-by-authorities.html https://www.metriopharm.com/en/investor-news/2014/patent-protection-of-MP1032.html https://www.metriopharm.com/en/investor-news/2016/MP1032-Psoriasis-Financial-Calendar-Capital-Increase.html https://www.metriopharm.com/en/investor-news/2017/MetrioPharm-Investor-Relations-News-QII-2017.html https://www.metriopharm.com/en/news/2017/14.03.2017-MetrioPharm-gibt-positive-Top-Line-Ergebnisse-bekannt.html https://www.metriopharm.com/de/Investor-News/2017/MetrioPharm-Investor-Relations-News-QIII-2017.html https://www.metriopharm.com/en/news/2018/Press-Release-11-15-2018.html https://www.metriopharm.com/de/News/2018/09.10.2018-MetrioPharm-gibt-die-Praesentation-praeklinischer-Daten-zur-MP1032-basierten-Multiple-Sklerose-Therapie-im-Rahmen-der-ECTRIMS-Konferenz-2018-bekannt.html https://www.metriopharm.com/de/Investor-News/2018/QIV.html https://www.metriopharm.com/en/investor-news/2018/QIV.html https://www.metriopharm.com/de/Investor-News/2020/MetrioPharm-Investor-Relations-News-QV-2020-2.html https://www.metriopharm.com/de/Pipeline/Patentschutz-MP1032-MP1000.html https://www.metriopharm.com/de/Technologie/MP1000-Plattform.html https://www.metriopharm.com/en/pipeline/patents-for-MP1032.html https://www.metriopharm.com/de/News/2023/MetrioPharm-erhaelt-Orphan-Drug-Designation-fuer-die-Behandlung-von-Duchenne-Muskeldystrophie.html https://www.metriopharm.com/de/Ueber-uns/Management-Board.html https://www.metriopharm.com/en/about-us/Management-Board.html https://www.metriopharm.com/en/news/2016/Dr-Sylvie-Gregoire-new-Executive-President-MetrioPharm-Board-of-Directors.html https://www.metriopharm.com/de/Ueber-uns.html https://www.metriopharm.com/en/investor-news/2016/10th-Annual-General-Meeting-of-MetrioPharm-AG.html https://www.metriopharm.com/de/Investor-News/2016/MP1032-Psoriasis-Finanzkalender-Kapitalerhoehung.html https://www.metriopharm.com/de/Investoren/Generalversammlung.html https://www.metriopharm.com/en/about-us.html https://www.metriopharm.com/en/technology/Mechanism-of-Action.html https://www.metriopharm.com/en/investors/general-meeting.html https://www.metriopharm.com/en/news/25/04.09.2025-MetrioPharm-Changes-Board-of-Directors.html https://www.metriopharm.com/en/Contact/Privacy-policy.html https://www.metriopharm.com/de/News/2016/MetrioPharm-AG-verstaerkt-Management.html https://www.metriopharm.com/de/News/2015/Klinische-Single-Dose-Pruefung-von-MP1032-erfolgreich.html https://www.metriopharm.com/de/News/2014/MetrioPharm-gewinnt-renommierten-Senior-Medical-Advisor.html https://www.metriopharm.com/en/news/2015/single-dose-part-of-MP1032’s-first-in-man-clinical-trial-successful.html https://www.metriopharm.com/en/news/2014/MetrioPharm-AG-attracts-high-profile-pharma-executive.html https://www.metriopharm.com/de/Investor-News/2015/April-2015-Generalversammlung-der-MetrioPharm-AG.html https://www.metriopharm.com/de/Investor-News/2014/Grosse-Fortschritte-in-allenm-Schluesselmaerkten.html https://www.metriopharm.com/en/investor-news/2015/General-Assembly-of-MetrioPharm-AG-April-2015.html https://www.metriopharm.com/en/investor-news/2014/Patents-Developments-in-all-key-markets.html https://www.metriopharm.com/de/News/2017/Patentschutz-MP1032-Japan.html.html https://www.metriopharm.com/en/news/2017/Announces-Positive-Top-Line-Results-from-a-Phase-IIa-Study.html https://www.metriopharm.com/en/investor-news/2017/IR-News-Quarter-1.html https://www.metriopharm.com/de/Investor-News/2017/MetrioPharm-Investor-Relations-News-QII-2017.html https://www.metriopharm.com/de/Investor-News/2018/MetrioPharm-Investor-Relations-News-QIII-2018.html https://www.metriopharm.com/en/investor-news/2018/MetrioPharm-Investor-Relations-News-QIII-2018.html https://www.metriopharm.com/de/News/2018/Pressemitteilung-vom-15112018.html https://www.metriopharm.com/en/news/2018/09.10.2018-MetrioPharm-Announces-Presentation-of-Preclinical-Data-on-MP1032-in-Multiple-Sclerosis-Therapy-at-ECTRIMS-Congress-2018.html https://www.metriopharm.com/de/Investor-News/2020/MetrioPharm-Investor-Relations-News-Update-24112020.html https://www.metriopharm.com/de/Investor-News/2021/MetrioPharm-Investor-Relations-News-QIV-2021.html https://www.metriopharm.com/de/News/2022/Last-Patient-Out-MetrioPharm-finalisiert-Klinische-Phase-II-Studie-in-COVID-19.html https://www.metriopharm.com/de/Ueber-uns/wissenschaftlicher-beirat.html https://www.metriopharm.com/de/Technologie/Wirkmechanismus.html https://www.metriopharm.com/de/News/2024/wissenschaftlicher-beirat.html https://www.metriopharm.com/en/news/25/12.09.2025-MetrioPharm-Thelen-new-CSO.html https://www.metriopharm.com/en/technology/Safety.html https://www.metriopharm.com/de/News/2026/10.03.2026-MetrioPharm-gibt-Aenderung-im-Verwaltungsrat-bekannt.html https://www.metriopharm.com/de/News/2025/12.09.2025-MetrioPharm-Thelen-CSO.html https://www.metriopharm.com/de/News/2026/11.03.2026-Prof-Dr-Steffen-Stuerzebecher-neuer-CMO.html https://www.metriopharm.com/en/news/2026/11.03.2026-Prof.-Dr.-Steffen-Stuerzebecher-new-CMO.html https://www.metriopharm.com/en/news/2026/10.03.2026-MetrioPharm-Announces-Change-to-its-Board-of-Directors.html https://www.metriopharm.com/de/Technologie.html https://www.metriopharm.com/de/Investor-News/2016/10-Generalversammlung.html https://www.metriopharm.com/de/Kontakt/Datenschutz.html https://www.metriopharm.com/de/News/2016/Dosierung-erster-Patienten-in-klinischer-Phase-IIa-Studie-MP1032-CT02.html https://www.metriopharm.com/en/about-us/Scientific-Advisory-Board.html https://www.metriopharm.com/en/Contact/imprint.html https://www.metriopharm.com/en/technology.html https://www.metriopharm.com/de/News/2015/Metriopharm-setzt-neue-Massstaebe-bei-Gefaessstuetzen.html https://www.metriopharm.com/de/News/2014/Phase-I-der-naechste-Entwicklungsschritt.html https://www.metriopharm.com/en/news/2016/MetrioPharm-announces-first-patients-dosed-in-a-clinical-phase-IIa-trial.html https://www.metriopharm.com/en/news/2015/start-of-phase-1-clinical-trial-with-a-novel-macrophage-modulator.html https://www.metriopharm.com/en/news/2014/Phase-I-the-next-step.html https://www.metriopharm.com/de/Investor-News/2014/Meilensteine-auf-dem-Weg-zu-einem-neuen-Medikament.html https://www.metriopharm.com/en/investor-news/2016/P1032-Phase-II-Preparation-Well-on-Track.html https://www.metriopharm.com/en/investor-news/2014/MP1032-Milestones-on-the-route-to-a-new-drug.html https://www.metriopharm.com/en/news/2017/Patent-Protection-MP1032-Japan.html https://www.metriopharm.com/de/Investor-News/2017/IR-News-Quartal-1.html https://www.metriopharm.com/de/Investor-News/2018/MetrioPharm-Investor-Relations-News-QII-2018.html https://www.metriopharm.com/en/investor-news/2018/MetrioPharm-Investor-Relations-News-QII-2018.html https://www.metriopharm.com/de/News/2018/Pressemitteilung-vom-14082018.html https://www.metriopharm.com/en/news/2018/Press-Release-08-2018.html https://www.metriopharm.com/en/investor-news/2019/MetrioPharm-Investor-Relations-News-QIV-2019.html https://www.metriopharm.com/de/Investor-News/2020/MetrioPharm-Investor-Relations-News-Update.html https://www.metriopharm.com/en/investor-news/2020/Investor-Relations-News-QIV-2020-2.html https://www.metriopharm.com/de/Ueber-uns/Jobs-Stellenangebote.html https://www.metriopharm.com/de/Investor-News/2021/MetrioPharm-Investor-Relations-News-QIII-2021.html https://www.metriopharm.com/de/News/2022/Pressemitteilung-march-2022.html https://www.metriopharm.com/de/News/2024/Pressemitteilung-MetrioPharm-veroeffentlicht-Studiendaten-die-die-Wirkung-einer-Host-Directed-Therapy-in-COVID-19-zeigen.html https://www.metriopharm.com/de/News/2025/MP1032-Orphan-Drug-Designation-DE.html https://www.metriopharm.com/de/Pipeline.html https://www.metriopharm.com/de/Kontakt/Impressum.html https://www.metriopharm.com/de/News/2016/Start-klinische-Phase-IIa-zur-Untersuchung-Leitsubstanz-MP1032-bei-Psoriasis.html https://www.metriopharm.com/de/Investor-News/2016/MP1032-Phase-II-Studie-mit-Patienten.html https://www.metriopharm.com/en/pipeline.html https://www.metriopharm.com/de/News/2015/Start-der-klinischen-Phase-1-Studie-mit-neuem-Makrophagen-Modulator.html https://www.metriopharm.com/de/News/2014/internationaler-Autoimmunkongress-in-Nizza.html https://www.metriopharm.com/en/news/2016/Go-Ahead-for-the-Clinical-Phase-II-Trial.html https://www.metriopharm.com/en/news/2015/regulatory-approval-to-initiate-clinical-development-of-MP1032.html https://www.metriopharm.com/en/news/2014/9th-International-Congress-on-Autoimmunity-(Nice).html https://www.metriopharm.com/de/Investor-News/2015/klinische-Studie-Phase-I-MP1032.html https://www.metriopharm.com/en/investor-news/2015/our-first-clinical-Study-in-man.html https://www.metriopharm.com/de/News/2018/MetrioPharm-stellt-klinische-Daten-der-Phase-IIa-Psoriasis-Studie-im-Rahmen-der-5.-WPPAC-in-Stockholm-vor.html https://www.metriopharm.com/de/Investor-News/2018/MetrioPharm-Investor-Relations-News-QI-2018.html https://www.metriopharm.com/en/investor-news/2018/MetrioPharm-Investor-Relations-News-QI-2018.html https://www.metriopharm.com/en/news/2018/MetrioPharm-Presents-Clinical-Phase-IIa-Psoriasis-Study-Data-at-the-5th-WPPAC-in-Stockholm.html https://www.metriopharm.com/en/investor-news/2019/MetrioPharm-Investor-Relations-News-QIII-2019.html https://www.metriopharm.com/de/Investor-News/2020/MetrioPharm-Investor-Relations-News-QIV-2020.html https://www.metriopharm.com/en/investor-news/2020/MetrioPharm-Investor-Relations-News-Update-24.11.2020.html https://www.metriopharm.com/de/Investor-News/2021/Investor-Relations-News-QII-2021.html https://www.metriopharm.com/en/investor-news/2021/MetrioPharm-Investor-Relations-News-QIII-2021.html https://www.metriopharm.com/en/investor-news/2021/MetrioPharm-Investor-Relations-News-QIV-2021.html https://www.metriopharm.com/de/Technologie/sicherheit-mp1032.html https://www.metriopharm.com/en/about-us/Career.html https://www.metriopharm.com/de/News/2025/04.09.2025-MetrioPharm-Aenderungen-Verwaltungsrat.html https://www.metriopharm.com/en/investors.html https://www.metriopharm.com/de/Investor-News/2019/MetrioPharm-Investor-Relations-News-QIV-2019.html https://www.metriopharm.com/de/Investor-News/2020/IR-News-Q3-2020.html https://www.metriopharm.com/de/News/2016/Weitere-Grundpatente-fuer-Leitsubstanz-MP1032.html https://www.metriopharm.com/de/News/2015/Bewilligung-zum-Start-der-klinischen-Entwicklung-von-MP1032.html https://www.metriopharm.com/de/News/2014/Auf-dem-Weg-zu-einem-neuen-Medikament.html https://www.metriopharm.com/en/news/2016/new-basic-patents-granted-for-MP1032.html https://www.metriopharm.com/en/news/2014/MetrioPharm-Milestones-on-the-route-to-a-new-drug.html https://www.metriopharm.com/de/Investor-News/2016/MetrioPharm-Investor-Relation-News-Jahresrueckblick-2016.html https://www.metriopharm.com/de/News/2018/29.5.2018-MetrioPharm-gibt-die-Praesentation-wissenschaftlicher-Daten-zum-Wirkmechanismus-von-MP1032-bekannt.html https://www.metriopharm.com/en/news/2018/MetrioPharm-gibt-die-Praesentation-wissenschaftlicher-Daten-zum-Wirkmechanismus-von-MP1032-bekannt.html https://www.metriopharm.com/de/Investor-News/2019/MetrioPharm-Investor-Relations-News-QIII-2019.html https://www.metriopharm.com/en/investor-news/2019/MetrioPharm-Investor-Relations-News-QII-2019.html https://www.metriopharm.com/en/investor-news/2020/MetrioPharm-Investor-Relations-News-Update.html https://www.metriopharm.com/de/Investor-News/2021/Investor-Relations-News-QI-2021.html https://www.metriopharm.com/en/investor-news/2021/Investor-Relations-News-QII-2021.html https://www.metriopharm.com/de/News/2025/Stephan-Rietiker-neuer-Verwaltungsratspraesident.html https://www.metriopharm.com/de/Investor-News/2022/MetrioPharm-Investor-Relations-News-QIV-2022.html https://www.metriopharm.com/de/Investoren.html https://www.metriopharm.com/de/News/2018/MetrioPharm-AG-gibt-Dosierung-des-ersten-Patienten-in-klinischer-Phase-II-Studie-fuer-MP1032-zur-Behandlung-von-mittelschwerer-bis-schwerer-chronischer-Plaque‐Psoriasis-bekannt.html https://www.metriopharm.com/en/press.html https://www.metriopharm.com/en/news/2018/Press-Release-03-2018.html https://www.metriopharm.com/en/investor-news/2019/MetrioPharm-Investor-Relations-News-QI-2019.html https://www.metriopharm.com/de/Investor-News/2020/Investor-Relations-News-QII-2020.html https://www.metriopharm.com/de/Investor-News/2019/MetrioPharm-Investor-Relations-News-QII-2019.html https://www.metriopharm.com/de/News/2019/pressemitteilung-161019.html https://www.metriopharm.com/en/investor-news/2020/MetrioPharm-Investor-Relations-News-QIV-2020.html https://www.metriopharm.com/de/News/2020/COVID-19-Therapeutikum.html https://www.metriopharm.com/de/Investor-News/2021/Investor-Relations-News-Update-26022021.html https://www.metriopharm.com/en/investor-news/2021/Investor-Relations-News-QI2021.html https://www.metriopharm.com/de/Investor-News/2022/Investor-Relations-News-QIII-2022.html https://www.metriopharm.com/en/investor-news/2022/MetrioPharm-Investor-Relations-News-QIV-2022.html https://www.metriopharm.com/de/News/2025/17042025-Vier-neue-Mitglieder-in-den-Verwaltungsrat-der-MetrioPharm-AG-gewaehlt.html https://www.metriopharm.com/en/Contact.html https://www.metriopharm.com/de/Presse.html https://www.metriopharm.com/de/Investor-News/2022/MetrioPharm-Investor-Relations-News-QII-2022.html https://www.metriopharm.com/de/Investor-News/2019/MetrioPharm-Investor-Relations-News-QI-2019.html https://www.metriopharm.com/en/news/2019/press-release-161019.html https://www.metriopharm.com/de/Investor-News/2020/MP-Investor-Relations-News-QI-2020.html https://www.metriopharm.com/en/investor-news/2020/IR-News-Q3-2020.html https://www.metriopharm.com/de/News/2020/praeklinische-Daten-MP1032-in-COVID-19-veroeffentlicht.html https://www.metriopharm.com/en/news/2020/Publication-MP1032-Preclinical-Data-in-COVID-19.html https://www.metriopharm.com/en/news/2020/COVID-19-Therapeutic-Agent-MetrioPharm-Prepares-to-Conduct-a-Phase-II-Clinical-Trial-24112020.html https://www.metriopharm.com/en/investor-news/2021/Investor-Relations-News-Update-27022021.html https://www.metriopharm.com/de/News/2021/MetrioPharm-unterzeichnet-Foerdervertrag-der-Europaeischen-Kommission-ueber-7.9-Mio-Euro.html https://www.metriopharm.com/en/news/25/Stephan-Rietiker-Chairman-of-the-Board-of-MetrioPharm-AG.html https://www.metriopharm.com/en/news/2021/MetrioPharm-Signs-European-Commission-Grant-Agreement-for-7.9-Million.html https://www.metriopharm.com/en/investor-news/2022/Investor-Relations-News-QIII-2022.html https://www.metriopharm.com/en/news/2022/Topline-Data-of-its-Phase-IIa-Study-of-MP1032-in-COVID-19-Patients.html https://www.metriopharm.com/en/news/2023/October-MetrioPharm-Receives-Rare-Pediatric-Disease-Designation-(RPDD)-for-MP1032-from-the-U.S.-FDA.html https://www.metriopharm.com/en/news/2024/scientific-advisory-board.html https://www.metriopharm.com/en/news/25/17042025-Four-new-members-elected-to-the-Board-of-Directors-of-MetrioPharm-AG.html https://www.metriopharm.com/en/news/25/29.07.2025-MP1032-Orphan-Drug-Designation-EN.html https://www.metriopharm.com/de/Kontakt.html https://www.metriopharm.com/en/news/2022/Preclinical-Experiments-in-Duchenne-Muscular-Dystrophy-(DMD).html https://www.metriopharm.com/de/Investor-News/2020/MetrioPharm-Investor-Relations-News-QI-2020.html https://www.metriopharm.com/en/news/2021/Press-Release-MetrioPharm-Doses-First-Patient-in-Phase-IIa-Study-of-MP1032-in-COVID-19.html https://www.metriopharm.com/en/news/2019/Sven-Zimmermann-Joins-MetrioPharm-as-CFO.html https://www.metriopharm.com/en/news/2020/MetrioPharm-Successfully-Completes-Study-in-COPD-Model.html https://www.metriopharm.com/en/investor-news/2020/Investor-Relations-News-QII-2020.html https://www.metriopharm.com/de/News/2019/Duplikat-von-23.07.2019-Sven-Zimmermann-verstaerkt-als-CFO-das-Management-der-MetrioPharm-AG.html https://www.metriopharm.com/de/News/2020/MetrioPharm-erfolgreiche-Studie-in-COPD-Modell.html https://www.metriopharm.com/de/News/2021/Pressemitteilung-Erster-COVID-19-Patient-erhaelt-Wirkstoff-MP1032-in-Phase-IIa-Studie.html https://www.metriopharm.com/de/Investor-News/2022/Investor-Relations-News-QI-2022.html https://www.metriopharm.com/en/investor-news/2022/MetrioPharm-Investor-Relations-News-QII-2022.html https://www.metriopharm.com/en/news/2023/MetrioPharm-Receives-Orphan-Drug-Designation-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html https://www.metriopharm.com/en/news/2024/Press-Release-MetrioPharm-Publishes-First-Trial-Data-Showing-Effects-of-Host-Directed-Therapy-in-COVID-19.html https://www.metriopharm.com/de/News/2019/17-06-19-Klinische-Phase-II-Studie-Psoriasis-abgeschlossen.html https://www.metriopharm.com/en/news/2019/PressRelease-June-2019-MetrioPharm-Last-Patient-Last-Visit.html https://www.metriopharm.com/en/investor-news/2020/MP-Investor-Relations-News-QI-2020.html https://www.metriopharm.com/de/News/2021/Pressemitteilung-MetrioPharm-erhoeht-Eigenkapital.html https://www.metriopharm.com/en/news/2021/PressRelease-MetrioPharm-AG-Strengthens-Equity.html https://www.metriopharm.com/en/news/2022/Last-Patient-Out-MetrioPharm-Completes-Clinical-Phase-II-Trial-in-COVID-19.html https://www.metriopharm.com/en/investor-news/2022/Investor-Relations-News-QI-2022.html https://www.metriopharm.com/de/Investor-News/2023/MetrioPharm-Investor-Relations-News-QIV-2023.html https://www.metriopharm.com/en/news/2019/MetrioPharm-AG-veroeffentlicht-Geschaeftsbericht-2018.html https://www.metriopharm.com/de/News/2019/MetrioPharm-AG-veroeffentlicht-Geschaeftsbericht-2018.html https://www.metriopharm.com/en/investor-news/2020/Investor-Relations-News-I-2020.html https://www.metriopharm.com/de/News/2021/Pressemitteilung-Thomas-Christely-verstaerkt-Management-der-MetrioPharm-AG-als-CEO.html https://www.metriopharm.com/en/news/2021/Press-Release-Thomas-Christely-joins-management-of-MetrioPharm-AG-as-CEO.html https://www.metriopharm.com/en/news/2022/press-release-march-2022.html https://www.metriopharm.com/de/Investor-News/2023/MetrioPharm-Investor-Relations-News-QIII-2023.html https://www.metriopharm.com/en/investor-news/2023/MetrioPharm-Investor-Relations-News-QIV-2023.html https://www.metriopharm.com/de/News/2021/28072021-MetrioPharm-von-Europaeischer-Kommission-fuer-Foerderung-im-Rahmen-des-HERA-Incubator-ausgewaehlt.html https://www.metriopharm.com/en/news/2019/news-barry-frankel-senior-vice-president.html https://www.metriopharm.com/de/News/2019/news-barry-frankel-senior-vice-president.html https://www.metriopharm.com/en/news/2021/07-28-Press-Release-MetrioPharm-Selected-by-European-Commission-for-Funding-as-Part-of-the-HERA-Incubator”.html https://www.metriopharm.com/de/Investor-News/2023/Investor-Relations-News-QII-2023.html https://www.metriopharm.com/en/investor-news/2023/MetrioPharm-Investor-Relations-News-QIII-2023.html https://www.metriopharm.com/de/News/2019/MetrioPharm-Pressemitteilung-Last-Patient-In.html https://www.metriopharm.com/en/news/2019/MetrioPharm-Press-Release-Last-Patient-In.html https://www.metriopharm.com/en/news/2021/press-release-patent-protection.html https://www.metriopharm.com/de/News/2021/pressemitteilung-patentschutz.html https://www.metriopharm.com/de/Investor-News/2025/Investor-Newsletter-QIV-2025-DE.html https://www.metriopharm.com/en/investor-news/2023/Investor-Relations-News-QII-2023.html https://www.metriopharm.com/de/Investor-News/2023/Investor-Relations-News-QI-2023.html https://www.metriopharm.com/de/Investor-News/2024/Investor-Update-QIV-2024.html https://www.metriopharm.com/de/Investor-News/2025/Invest-Newsletter-QII-2025.html https://www.metriopharm.com/en/investor-news/2023/Investor-Relations-News-QI-2023.html https://www.metriopharm.com/de/News/2019/MetrioPharm-AG-Pressemitteilung-Februar2019.html https://www.metriopharm.com/en/news/2019/MetrioPharm-AG-PressRelease-February2019.html https://www.metriopharm.com/de/News/2021/Pressemitteilung-08042021.html https://www.metriopharm.com/en/news/2021/PressRelease-08042021.html https://www.metriopharm.com/de/Investor-News/2024/Investor-Relations-News-QIII-2024.html https://www.metriopharm.com/en/investor-news/2024/Investor-Update-QIV-2024.html https://www.metriopharm.com/en/investor-news/2025/Invest-Newsletter-QII-2025.html https://www.metriopharm.com/de/News/2021/Pressemitteilung-05032021-MetrioPharm-AG-Managementveraenderung.html https://www.metriopharm.com/en/news/2021/press-release-MetrioPharmAG-Announces-Change-In-Management-Team.html https://www.metriopharm.com/de/Investor-News/2024/MetrioPharm-Investor-Relation-News-QII-2024.html https://www.metriopharm.com/en/investor-news/2024/Investor-Relations-News-QIII-2024.html https://www.metriopharm.com/de/Investor-News/2025/MetrioPharm-Investor-Update-QI-2025.html https://www.metriopharm.com/en/investor-news/2025/MetrioPharm-Investor-Update-QI-2025.html https://www.metriopharm.com/en/investor-news/2025/Investor-Newsletter-QIV-2025-EN.html https://www.metriopharm.com/de/Investor-News/2024/MetrioPharm-Investor-Relations-News-QI-2024.html https://www.metriopharm.com/en/investor-news/2024/MetrioPharm-Investor-Relations-News-QII-2024.html https://www.metriopharm.com/en/investor-news/2024/MetrioPharm-Investor-Relations-News-QI-2024.html